Number of participants experiencing at least one severe adverse event · people with early‐stage TTR‐FAP
It is very uncertain whether tafamidis changes number of participants experiencing at least one severe adverse event compared with placebo (very low certainty).
1 finding from 1 review
Disability due to FAP progression (expressed as the change in Kumamoto Score) Scale from: 0 (normal) to 102 (worst disease severity). · people with TTR‐FAP
1 finding from 1 review
Severity of peripheral neuropathy (expressed as the change in NIS+7) Scale from: 0 (normal) to 270 (total impairment) · people with TTR‐FAP
1 finding from 1 review
Physical quality of life · people with TTR‐FAP
1 finding from 1 review
Incomplete recovery at end of study № of participants: 766 (3 RCTs) · Bell's palsy
Antivirals plus corticosteroids showed no clear difference in incomplete recovery at end of study № of participants: 766 (3 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (low certainty).
1 finding from 1 review
RR 0.81 [0.38, 1.74]
Studies not reported
Low
Motor synkinesis or crocodile tears № of participants: 469 (2 RCTs) · Bell's palsy
Antivirals plus corticosteroids probably leads to lower motor synkinesis or crocodile tears № of participants: 469 (2 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (moderate certainty).
1 finding from 1 review
RR 0.56 [0.36, 0.87]
Studies not reported
Moderate
Adverse events № of participants: 656 (2 RCTs) · Bell's palsy
It is very uncertain whether antivirals plus corticosteroids changes adverse events № of participants: 656 (2 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (very low certainty).
1 finding from 1 review
RR 1.17 [0.81, 1.68]
Studies not reported
Very low
Acquisition of the ability to sit · children with SMA type I
1 finding from 1 review
Acquisition of the ability to stand · children with SMA type I
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in motor score after two years · children with SMA type I
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events attributable to treatment · children with SMA type I
1 finding from 1 review
Severe adverse events attributable to treatment · children with SMA type I
1 finding from 1 review
Time from birth until death or full‐time ventilation · children with SMA type I
1 finding from 1 review
Acquisition of head control · children with SMA type I
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain at 6 months or more; all doses Assessed by change from baseline, using a 0‐ to 100‐mm VAS, where higher scores indicate more pain) · people with diabetic peripheral neuropathy
1 finding from 1 review
Functional impairment and disability Assessed by NIS or NDS at 6 months or more · people with diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Impairment of sensation Assessed by quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more · people with diabetic peripheral neuropathy
1 finding from 1 review
Impairment of sensation Assessed by quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more · people with diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptom quality and severity Assessed by change in symptom score on a validated screening questionnaire (NSS or MNSI) at 6 months or more · people with diabetic peripheral neuropathy
1 finding from 1 review
no estimate extracted
2 participants
GRADE not reported
Adverse events: any adverse event, adverse events requiring withdrawal, and serious adverse events · people with diabetic peripheral neuropathy
1 finding from 1 review